Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
molsidomine
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Molsidomine is an orally active, long-acting vasodilator of the syndnone class used primarily for the prevention and long-term treatment of stable and unstable angina pectoris, including in patients with left heart failure or following acute myocardial infarction. It acts as a prodrug that is metabolized in the liver to linsidomine (SIN-1), which then releases nitric oxide (NO). The NO stimulates soluble guanylate cyclase, increasing cyclic GMP levels and leading to relaxation of vascular smooth muscle, resulting in vasodilation and reduced myocardial oxygen demand. Unlike organic nitrates, molsidomine does not induce tolerance with prolonged use. It also has antiplatelet effects due to its mechanism of action[1][2][6][8].
- Brand names
- CorvasalCorvaton
- Other names
- MolsidominaMolsidominum
02
Targets
GUCY1A2 (Guanylate cyclase soluble subunit alpha-2)
Beyond the preview
Go deeper on molsidomine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on molsidomine.